Beyin-gut-mikrobiyota ekseni: Bağırsak mikrobiyotası ile beyin ve hastalık etkileşimleri arasındaki çift yönlü düzenleyici mekanizmalar üzerine bir inceleme.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

ObjectiveTo synthesize current evidence on the bidirectional regulatory mechanisms of the Brain-Gut-Microbiota Axis (BGMA), its perturbation by external factors, and its clinical implications for neurodegenerative, psychiatric, metabolic, and gastrointestinal disorders.DesignNarrative review integrating preclinical and clinical evidence.Data sourcesPubMed/Medline, EMBASE, Cochrane Library searches (2000-2023) using keywords: "brain-gut-axis," "microbiota," "dysbiosis," "neuroinflammation," "SCFAs," "neurodegeneration," "psychobiotics."ResultsDiet, stress, antibiotics, and environment significantly alter gut microbiota composition (e.g., reducing diversity, shifting Firmicutes/Bacteroidetes (F/B) ratio). Dysbiosis disrupts BGMA communication via: (1) Neural pathways (vagus nerve modulation); (2) Immune activation (cytokine release, neuroinflammation); (3) Microbial metabolites (SCFAs, tryptophan derivatives, TMAO). These disruptions are associated with Alzheimer's disease (reduced Faecalibacterium, amyloid deposition), Parkinson's (elevated TMAO, α-synuclein aggregation), and depression (altered serotonin synthesis), though causality remains to be established in human studies.ConclusionThe BGMA is a critical mediator of systemic health. Dysbiosis contributes to disease pathogenesis through defined neural, immune, and metabolic pathways. Targeting the microbiota offers novel therapeutic strategies. Future research must prioritize translational studies validating microbial biomarkers and interventions in human cohorts.

İlgili konular